Tvardi Therapeutics, Inc. — Director's Dealing 2021

Mar 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cara Therapeutics, Inc. (CARA)
CIK: 0001346830
Period of Report: 2021-03-04

Reporting Person: CHALMERS DEREK T (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-04	Common Stock	A	10000	$0.00	Acquired	953614	Direct
2021-03-05	Common Stock	S	3103	$17.98	Disposed	950511	Direct

Footnotes

F1: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on March 4, 2021. Each RSU represents the contingent right to receive one share of common stock of the Issuer.

F2: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs, and does not represent a discretionary trade by the Reporting Person.